Two-Year Outcomes of Less Invasive Surfactant Administration Among Preterm Neonates
JAMA Network Open · 31.03.2026 · 9 (3) · e263852
DOI: 10.1001/jamanetworkopen.2026.3852 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JAMA Network Open, online erschienen am 31.03.2026. Verfasst von Rebecca A Dorner und 7 weiteren Autor:innen. Beteiligte Einrichtung: Neonatal Research Institute, Sharp Mary Birch Hospital for Women & Newborns, San Diego, California. Hauptthemen laut MEDLINE: Pulmonary Surfactants, Infant, Premature, Continuous Positive Airway Pressure, Respiratory Distress Syndrome, Newborn. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance In preterm neonates supported with continuous positive airway pressure (CPAP), early caffeine administration and less invasive surfactant administration (LISA) results in a lower frequency of endotracheal intubation. It is unknown whether this regimen improves outcomes at a corrected age of 2 years in this population.
Objective
To determine whether LISA improves neurodevelopmental impairment (NDI) and pulmonary outcomes at a corrected age of 2 years. Design, Setting, and Participants This prespecified secondary analysis and follow-up of a randomized clinical trial was performed at 3 academic medical centers in California. Participants included infants born at gestational ages ranging from 24 weeks 0 days to 29 weeks 6 days with follow-up assessments available. Follow-up visits occurred from May 2, 2022, to April 3, 2025.
Interventions
Infants received intravenous caffeine by 2 hours of life followed by either less invasive surfactant administration (intervention group) or CPAP without initial surfactant administration (control group). Main Outcomes and Measures The primary outcome was the composite of death or moderate to severe NDI at a corrected age of 2 years, as measured by the Bayley Scales of Infant Development (BSID). Secondary outcomes included components of the BSID composite; the third edition of the Ages and Stages Questionnaire (ASQ-3); developmental screening; pulmonary outcomes of bronchodilator use, oral and/or inhaled corticosteroid use, or hospitalizations with respiratory diagnoses after discharge; and results of an autism screen.
Results
Of 180 randomized infants, 147 (81.7%) had follow-up assessments available (74 in the LISA group and 73 in the CPAP group); 75 infants (51.0%) were male. The mean (SD) gestational age at the time of the Bayley assessment was 24.6 (1.5) months corrected age for the LISA group and 24.7 (2.2) months corrected age for the CPAP group. The mean (SD) chronological age for the ASQ-3 was 28.1 (2.4) months for both groups. Death or moderate to severe NDI occurred in 17 of 74 children (23.0%) in the LISA group and 23 of 70 (32.9%) in the control group (odds ratio [OR], 1.56 [95% CI, 0.77-3.17]; P = .22). On the screening ASQ-3, infants in the LISA group had no statistically significant differences in rates of typical development (22 of 69 [31.9%] vs 12 of 67 [17.9%]; OR, 0.47 [95% CI, 0.21-1.04]; P = .06) and scores indicating possible delay (43 of 69 [62.3%] vs 47 of 67 [70.1%]; OR, 1.42 [95% CI, 0.70-2.90]; P = .34) compared with the control group. Children in the LISA group were more likely to have a mean (SD) fine motor z score in the reference range (−0.59 [1.10] vs −1.00 [1.01]; P = .03). There were no differences between the LISA and CPAP groups in bronchodilator use, oral and/or inhaled corticosteroid use, or postdischarge hospitalizations with respiratory diagnoses. Conclusions and Relevance In this secondary analysis of a randomized clinical trial of preterm infants supported with CPAP, early caffeine administration plus LISA did not reduce the incidence of death or moderate to severe NDI noted on the BSID. Infants who received LISA were more likely to have a fine motor domain score in the reference range on ASQ-3 developmental screen. Trial Registration ClinicalTrials.gov Identifier: NCT04209946
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Neonatal Research Institute, Sharp Mary Birch Hospital for Women & Newborns, San Diego, California.
- Loma Linda University Children's Hospital, Loma Linda, California.
- University of California Irvine Medical Center, Irvine.
Zitieren
APA
Dorner, R. A., Morales, A., Banerji, A., Uy, C., Ines, F., Finer, N., Vaucher, Y., & Katheria, A. C. (2026). Two-Year Outcomes of Less Invasive Surfactant Administration Among Preterm Neonates. JAMA Network Open, 9(3), e263852. https://doi.org/10.1001/jamanetworkopen.2026.3852
Vancouver
Dorner RA, Morales A, Banerji A, Uy C, Ines F, Finer N, et al. Two-Year Outcomes of Less Invasive Surfactant Administration Among Preterm Neonates. JAMA Network Open. 2026;9(3):e263852. doi:10.1001/jamanetworkopen.2026.3852
BibTeX
@article{Dorner2026,
author = {Dorner, Rebecca A and Morales, Ana and Banerji, Anamika and Uy, Cherry and Ines, Felix and Finer, Neil and Vaucher, Yvonne and Katheria, Anup C},
title = {Two-Year Outcomes of Less Invasive Surfactant Administration Among Preterm Neonates},
journal = {JAMA Network Open},
year = {2026},
volume = {9},
number = {3},
pages = {e263852},
doi = {10.1001/jamanetworkopen.2026.3852}
}
EUVIMED